Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by CEL-SCI Corporation < Previous 1 2 Next > CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population June 18, 2024 From CEL-SCI Corporation Via Business Wire Tickers CVM Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor June 06, 2024 From CEL-SCI Corporation Via Business Wire Tickers CVM CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results May 16, 2024 From CEL-SCI Corporation Via Business Wire Tickers CVM CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer May 08, 2024 From CEL-SCI Corporation Via Business Wire Tickers CVM CEL-SCI Appoints Mario Gobbo to Its Board of Directors April 23, 2024 From CEL-SCI Corporation Via Business Wire Tickers CVM CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology March 19, 2024 From CEL-SCI Corporation Via Business Wire Tickers CVM CEL-SCI Corporation Issues Letter to Shareholders March 06, 2024 From CEL-SCI Corporation Via Business Wire Tickers CVM CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results February 15, 2024 From CEL-SCI Corporation Via Business Wire Tickers CVM CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock February 13, 2024 From CEL-SCI Corporation Via Business Wire Tickers CVM CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock February 09, 2024 From CEL-SCI Corporation Via Business Wire Tickers CVM CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug February 06, 2024 From CEL-SCI Corporation Via Business Wire Tickers CVM European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine® January 31, 2024 From CEL-SCI Corporation Via Business Wire Tickers CVM CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments December 22, 2023 From CEL-SCI Corporation Via Business Wire Tickers CVM UK’S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI’s Multikine as Potential New Standard of Care for Head & Neck Cancer December 04, 2023 From CEL-SCI Corporation Via Business Wire Tickers CVM CEL-SCI Announces Closing of $5 Million Public Offering of Common Stock November 20, 2023 From CEL-SCI Corporation Via Business Wire Tickers CVM CEL-SCI Announces Pricing of $5 Million Offering of Common Stock November 16, 2023 From CEL-SCI Corporation Via Business Wire Tickers CVM CEL-SCI Issues Letter to Shareholders October 30, 2023 From CEL-SCI Corporation Via Business Wire Tickers CVM CEL-SCI Releases Video Detailing Recent Phase 3 Findings & its Plans to Seek Immediate Regulatory Approvals October 24, 2023 From CEL-SCI Corporation Via Business Wire Tickers CVM 5-Year Head & Neck Cancer Survival Increased From 45% to 73% in CEL-SCI’s Target Population, Cutting Risk of Death in Half, as Presented at Leading Cancer Conference ESMO 2023 October 23, 2023 From CEL-SCI Corporation Via Business Wire Tickers CVM CEL-SCI Readies Its Multikine Manufacturing Facility for Commercial Scale Production October 19, 2023 From CEL-SCI Corporation Via Business Wire Tickers CVM CEL-SCI Files Request With the UK’s MHRA Regarding Path to Approval for Multikine in the Treatment of Head & Neck Cancer October 05, 2023 From CEL-SCI Corporation Via Business Wire Tickers CVM CEL-SCI Submits Scientific Advice Filing to European Medicines Agency (EMA) for Multikine in the Treatment of Head & Neck Cancer September 26, 2023 From CEL-SCI Corporation Via Business Wire Tickers CVM CEL-SCI Corporation Reports Third Quarter Fiscal 2023 Financial Results August 11, 2023 From CEL-SCI Corporation Via Business Wire Tickers CVM CEL-SCI Announces Closing of Public Offering July 20, 2023 From CEL-SCI Corporation Via Business Wire Tickers CVM CEL-SCI Announces Pricing of Public Offering July 17, 2023 From CEL-SCI Corporation Via Business Wire Tickers CVM CEL-SCI Announces Proposed Public Offering of Common Stock July 17, 2023 From CEL-SCI Corporation Via Business Wire Tickers CVM CEL-SCI Concludes Positive Meeting With U.S. FDA Concerning Multikine’s Approval for Head & Neck Cancer July 14, 2023 From CEL-SCI Corporation Via Business Wire Tickers CVM CEL-SCI Reports Phase 3 Tumor PD-L1 Biomarker Data Demonstrate Multikine’s Increased Efficacy and Points to Potential for Combination With Checkpoint Inhibitors for Head & Neck Cancer July 11, 2023 From CEL-SCI Corporation Via Business Wire Tickers CVM CEL-SCI to Present Novel Data at AHNS 11th International Conference on Head and Neck Cancer—New Patent to Be Filed June 22, 2023 From CEL-SCI Corporation Via Business Wire Tickers CVM Histopathology and Tumor Biomarker Analysis Confirm CEL-SCI’s Multikine Significantly Prolonged Overall Survival in Head & Neck Cancer—Phase 3 Data Presented at ESTRO 2023 May 15, 2023 From CEL-SCI Corporation Via Business Wire Tickers CVM < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.